Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy

被引：1
|
作者：
Mueschen, Lars H. [1 ]
Koerner, Gudrun [1 ]
Gingele, Stefan [1 ]
Haenselmann, Anja [2 ]
Bavendiek, Udo [2 ]
Skripuletz, Thomas [1 ]
机构：
[1] Hannover Med Sch, Dept Neurol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Hannover Med Sch, Dept Cardiol & Angiol, Hannover, Germany
来源：
MUSCLE & NERVE | 2021年 / 64卷 / 03期
关键词：
DISABILITY SCALE;
D O I：
10.1002/mus.27338
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E11 / E13
页数：3
相关论文
共 50 条
  • [11] Long-term Integrated Safety of Patisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
    Gillmore, Julian
    Berk, John
    Dispenzieri, Angela
    Polydefkis, Michael
    Gonzalez-Duarte, Alejandra
    Sekijima, Yoshiki
    Sweetser, Marianne T.
    Arum, Seth
    Wang, Jing Jing
    White, Matthew T.
    Maurer, Mathew
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S67 - S68
  • [12] Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Gillmore, J.
    Berk, J.
    Dispenzieri, A.
    Polydefkis, M.
    Gonzalez-Duarte, A.
    Sekijima, Y.
    Sweetser, M. T.
    Arum, S.
    Wang, J. J.
    White, M. T.
    Maurer, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2129 - 2129
  • [13] Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy"
    Lin, Hollis
    Agarwal, Sonalee
    Betts, Marissa
    Fahrbach, Kyle
    Chitnis, Madhura
    Polydefkis, Michael
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (12) : 1529 - 1530
  • [14] Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
    Nie, Tina
    Heo, Young-A
    Shirley, Matt
    DRUGS, 2023, 83 (15) : 1425 - 1432
  • [15] Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
    Tina Nie
    Young-A Heo
    Matt Shirley
    Drugs, 2023, 83 : 1425 - 1432
  • [16] Impact of baseline neuropathy stage in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with or without patisiran treatment
    Kyriakides, T.
    Brannagan, T.
    Lin, H.
    Wang, Y.
    Conceicao, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 190 - 190
  • [17] Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis
    Gertz, Morie A.
    Scheinberg, Morton
    Waddington-Cruz, Marcia
    Heitner, Stephen B.
    Karam, Chafic
    Drachman, Brian
    Khella, Sami
    Whelan, Carol
    Obici, Laura
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (08) : 701 - 711
  • [18] LONG-TERM, INTEGRATED CARDIAC SAFETY OF PATISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
    Dispenzieri, Angela
    Gillmore, Julian
    Polydefkis, Michael
    Plante-Bordeneuve, Violaine
    Schmidt, Hartmut
    Berber, Erhan
    Wang, Jing Jing
    Sweetser, Marianne
    White, Matthew
    Maurer, Mathew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 690 - 690
  • [19] Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy"
    Salvo, E. M.
    Samjoo, I. A.
    Tran, D.
    Cameron, C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (12) : 1527 - 1528
  • [20] A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
    Ivan Urits
    Daniel Swanson
    Michael C. Swett
    Anjana Patel
    Kevin Berardino
    Ariunzaya Amgalan
    Amnon A. Berger
    Hisham Kassem
    Alan D. Kaye
    Omar Viswanath
    Neurology and Therapy, 2020, 9 : 301 - 315
12345